Protalix BioTherapeutics Issues 2021 Letter to Stockholders
- Wednesday, December 22, 2021, 7:03
- Finance
- Add a comment
CARMIEL, Israel, Dec. 22, 2021 /PRNewswire/ — Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant…
About the Author
adminasapcorp has written 41672 stories on this site.